Neoplasms

All Conditions

Rare Diseases

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Neuroendocrine Tumor

Pancreatic Neuroendocrine Tumor

Neuroepithelioma

Eligible consenting patients will undergo one-time biopsy, during which at least 3 tumors' core samples (total length of at least 6 cm) will be collected. Core tumor biopsies and 3 vials of whole blood and archived tumor specimens will be obtained for genomic testing analysis.

Lillian Siu, MD

Prospective study to obtain fresh tumor biopsies and three blood samples from patients with a confirmed histological or cytological diagnosis of well-differentiated neuroendocrine tumors (NETs) or well-differentiated pancreatic neuroendocrine tumors (PanNETs) for molecular profiling.

In this prospective study the aim is to obtain fresh tumor biopsies and three blood samples from patients with a confirmed histological or cytological diagnosis of well-differentiated neuroendocrine tumors (NETs) or well-differentiated pancreatic neuroendocrine tumors (PanNETs). Eligible population includes: NETs and PanNETs patients who have undergone or are undergoing treatment with targeted therapies and have shown prolonged clinical benefit, and NETs and PanNETs patients who have been treated with these agents and just recently progressed. RNA and DNA from fresh tumor biopsies and from mononuclear blood cells will be subjected to transcriptome sequencing and DNA sequencing analyses to evaluate possible genes of interest and related targetable pathways. Moreover, archived tumor samples will be requested from all patients to perform additional genomic testing. Remaining RNA and DNA will be banked for additional exploratory analyses (e.g. further genomic testing, or DNA copy number analysis, or epigenetic evaluations).

Fresh tumor tissue, 3 tubes of whole blood, archival tumor tissue

Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors

Princess Margaret Hospital, Canada

University Health Network, Toronto

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Prostatic Neoplasms

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Jinge Zhao, Dr.

Hao Zeng, Dr.

The investigators plan to perform multi-omics technologies, including genomic, transcriptomic, epigenomic and proteomic methods, in patients with metastatic prostate cancer, aiming at uncovering the mechanism of the tumor progression, identifying distinct tumor subtypes and finding new treatment targets.

Prostate cancer is the commonest malignancy and the second leading cause of tumor-related death among males worldwide. Though patients with early stage prostate cancer can obtain satisfactory therapeutic efficacy from radical prostatectomy or radiotherapy, the prognosis of men with metastatic prostate cancer (mPCa), especially metastatic castration-resistant prostate cancer (mCRPC), is still poor. Recent years have witnessed the rapid development of the high-throughput technologies, including genomic, transcriptomic, epigenomic and proteomic methods. These techniques are promising in uncovering the mechanism of the tumor progression, identifying distinct tumor subtypes and finding new treatment targets.

In the current prospective study, the investigators plan to perform multi-omics technologies in patients with mPCa, aiming at uncovering the mechanism of the tumor progression, identifying distinct tumor subtypes and finding new treatment targets.

A Multi-omics Study of Metastatic Prostate Cancer (MOSMPCA)

Mutation identified via whole-genome sequencing will be recored.

Determining the transcriptomic information of metastatic prostate cancer by performing whole transcriptome sequencing

Determining the epigenomic status of specific genes by performing DNA-methylation sequencing

Determing the expression status of centain proteins by performing immunohistochemistry in prostate biopsy specimen

Study title	NCT ID	Conditions	Eligibility	Organization
Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors	NCT02586844	Neuroendocrine ... Pancreatic Neur...	18 Years -	University Health Network, Toronto
Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors	NCT02586844	Neuroendocrine ... Pancreatic Neur...	18 Years -	University Health Network, Toronto
A Multi-omics Study of Metastatic Prostate Cancer (MOSMPCA)	NCT04660617	Prostate Cancer...	40 Years -	West China Hospital

Spots Global Cancer Trial Database for transcriptome sequencing